blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3367100

EP3367100 - METHOD FOR ASSISTING DETERMINATION OF INVASIVENESS OF MYXOFIBROSARCOMA, AND USE OF A KIT IN THE METHOD [Right-click to bookmark this link]
Former [2018/35]METHOD FOR ASSISTING DETERMINATION OF INVASIVENESS OF MYXOFIBROSARCOMA, AND KIT FOR DETERMINING INVASIVENESS OF MYXOFIBROSARCOMA USED IN METHOD
[2019/28]
StatusNo opposition filed within time limit
Status updated on  23.10.2020
Database last updated on 26.07.2024
FormerThe patent has been granted
Status updated on  15.11.2019
FormerGrant of patent is intended
Status updated on  08.07.2019
FormerRequest for examination was made
Status updated on  08.03.2019
FormerThe application has been published
Status updated on  27.07.2018
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
National Cancer Center
5-1-1, Tsukiji
Chuo-ku
Tokyo 1040045 / JP
For all designated states
Keio University
15-45 Mita 2-chome, Minato-ku
Tokyo 108-8345 / JP
For all designated states
SYSMEX CORPORATION
5-1 Wakinohama-Kaigandori 1-chome
Chuo-ku
Kobe-shi
Hyogo 651-0073 / JP
[2018/35]
Inventor(s)01 / Kikuta, Kazutaka
c/o Keio University School of Medicine 35
Shinanomachi, Shinjuku-ku
Tokyo, 1608582 / JP
02 / Nakamura, Masaya
c/o Keio University School of Medicine 35
Shinanomachi, Shinjuku-ku
Tokyo, 1608582 / JP
03 / Kawai, Akira
c/o National Cancer Center 5-1-1, Tsukiji, Chuo-ku
Tokyo, 1040045 / JP
04 / Kondo, Tadashi
c/o National Cancer Center 5-1-1, Tsukiji, Chuo-ku
Tokyo, 1040045 / JP
 [2018/35]
Representative(s)De Clercq & Partners
Edgard Gevaertdreef 10a
9830 Sint-Martens-Latem / BE
[2018/35]
Application number, filing date18158737.927.02.2018
[2018/35]
Priority number, dateJP2017003500127.02.2017         Original published format: JP 2017035001
[2018/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3367100
Date:29.08.2018
Language:EN
[2018/35]
Type: B1 Patent specification 
No.:EP3367100
Date:18.12.2019
Language:EN
[2019/51]
Search report(s)(Supplementary) European search report - dispatched on:EP18.06.2018
ClassificationIPC:G01N33/574
[2018/35]
CPC:
G01N33/57407 (EP); G01N2800/52 (EP); G01N2800/54 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/15]
Former [2018/35]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA27.02.2019
ME27.02.2019
Validation statesMA27.02.2019
MD27.02.2019
TN27.02.2019
TitleGerman:VERFAHREN ZUR UNTERSTÜTZUNG DER BESTIMMUNG DER INVASIVITÄT EINES MYXOFIBROSARKOMS UND VERWENDUNG EINES KITS IM VERFARHEN[2019/28]
English:METHOD FOR ASSISTING DETERMINATION OF INVASIVENESS OF MYXOFIBROSARCOMA, AND USE OF A KIT IN THE METHOD[2019/28]
French:PROCÉDÉ D'AIDE À LA DÉTERMINATION DU CARACTÈRE INVASIF DU MYXOFIBROSARCOME ET UTILISATION D'UN KIT DANS LE PROCÉDÉ[2019/28]
Former [2018/35]VERFAHREN ZUR UNTERSTÜTZUNG DER BESTIMMUNG DER INVASIVITÄT EINES MYXOFIBROSARKOMS UND KIT ZUR BESTIMMUNG DER INVASIVITÄT EINES MYXOFIBROSARKOMS HIERFÜR
Former [2018/35]METHOD FOR ASSISTING DETERMINATION OF INVASIVENESS OF MYXOFIBROSARCOMA, AND KIT FOR DETERMINING INVASIVENESS OF MYXOFIBROSARCOMA USED IN METHOD
Former [2018/35]PROCÉDÉ D'AIDE À LA DÉTERMINATION DU CARACTÈRE INVASIF DU MYXOFIBROSARCOME ET KIT PERMETTANT DE DÉTERMINER LE CARACTÈRE INVASIF DU MYXOFIBROSARCOME UTILISÉ DANS LE PROCÉDÉ
Examination procedure27.02.2019Amendment by applicant (claims and/or description)
27.02.2019Examination requested  [2019/15]
27.02.2019Date on which the examining division has become responsible
09.07.2019Communication of intention to grant the patent
12.11.2019Fee for grant paid
12.11.2019Fee for publishing/printing paid
12.11.2019Receipt of the translation of the claim(s)
Opposition(s)21.09.2020No opposition filed within time limit [2020/48]
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.02.2018
AL18.12.2019
AT18.12.2019
CY18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
ES18.12.2019
FI18.12.2019
HR18.12.2019
IT18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
MK18.12.2019
MT18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
TR18.12.2019
IE27.02.2020
LU27.02.2020
BE29.02.2020
FR29.02.2020
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
[2022/33]
Former [2022/27]HU27.02.2018
AL18.12.2019
AT18.12.2019
CY18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
ES18.12.2019
FI18.12.2019
HR18.12.2019
IT18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
MT18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
TR18.12.2019
IE27.02.2020
LU27.02.2020
BE29.02.2020
FR29.02.2020
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2021/10]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
ES18.12.2019
FI18.12.2019
HR18.12.2019
IT18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
IE27.02.2020
LU27.02.2020
BE29.02.2020
FR29.02.2020
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2021/07]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
ES18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
IE27.02.2020
LU27.02.2020
FR29.02.2020
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2020/50]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
ES18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
LU27.02.2020
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2020/47]AL18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
ES18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SK18.12.2019
SM18.12.2019
LU27.02.2020
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2020/40]AL18.12.2019
CZ18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2020/37]AL18.12.2019
CZ18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
PT13.05.2020
Former [2020/36]AL18.12.2019
CZ18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
PT13.05.2020
Former [2020/35]AL18.12.2019
CZ18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/32]AL18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/25]FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/23]FI18.12.2019
LT18.12.2019
LV18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/22]FI18.12.2019
LT18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
Former [2020/21]NO18.03.2020
Documents cited:Search[A]  - SHA LOU ET AL, "High-grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging", PROTEOMICS, DE, (20160601), vol. 16, no. 11-12, doi:10.1002/pmic.201500514, ISSN 1615-9853, pages 1802 - 1813, XP055469390 [A] 1-7 * the whole document *

DOI:   http://dx.doi.org/10.1002/pmic.201500514
 [A]  - KIM M ET AL, "Epigenetic down-regulation and suppressive role of DCBLD2 in gastric cancer cell proliferation and invasion", MOLECULAR CANCER RESE, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20080201), vol. 6, no. 2, doi:10.1158/1541-7786.MCR-07-0142, ISSN 1541-7786, pages 222 - 230, XP008135573 [A] 1-7 * the whole document *

DOI:   http://dx.doi.org/10.1158/1541-7786.MCR-07-0142
 [XP]  - KIKUTA KAZUTAKA ET AL, "Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxofibrosarcoma invasion identified by global protein expression profiling", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, NETHERLANDS, (20170629), vol. 1865, no. 9, doi:10.1016/J.BBAPAP.2017.06.023, ISSN 1570-9639, pages 1160 - 1166, XP085143908 [XP] 1-7 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bbapap.2017.06.023
by applicantUS2011293618
    - E. TOPKAS, European Journal of Cancer, vol. 50, no. 5, page S60
    - KOSHIKAWA K et al., Oncogene, (20020425), vol. 21, no. 18, pages 2822 - 8
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.